One first-in-human study and two deals in a single day sees companies blaze the ADC trail.

The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.

But JNJ-75276617 still has much to prove.

As a key mid-stage readout approaches for the group’s neoantigen immunotherapy, Gritstone still has much to prove.

Merck sees clinical setbacks in Keylynk-008, Leap-001 and Keyvibe-002.

The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.

Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.

Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.

The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.

Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.

AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.

Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.

Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.

Ideaya and GSK join Novartis and Roche in the Werner helicase inhibitor race.

But late-breaking data raise questions about lack of a dose response.

The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.

Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.

Initial data on Amgen’s AMG 193 give some Tango investors a headache.

AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.

Assets targeting PSMA and KRAS G12V, plus another gamma-delta Car-T therapy, feature among recently disclosed first-time clinical trial entrants.

Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.

With revumenib’s broader coverage Syndax tries to gain ground on Kura’s ziftomenib, but hits a new snag.

Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.

A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.

Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.

A 14% ORR with IDRX-42 in fourth-line GIST looks better than the 9% previously seen with Qinlock.

Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.

Merus still hopes for a future for MCLA-129, but the doors are closing.

And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.

A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.

The acquisition brings closure for Mirati at last, though some investors will feel disappointed.

Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?

The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.

Bristol, AbbVie and Jiangsu HengRui move to enter clinical trials with undisclosed mechanisms of action.

ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.

The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.

The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.

Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.

A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.

BeiGene regains rights to tislelizumab as another oncology asset blows up for Novartis.

After Exkivity signals another accelerated approval slowdown the Amgen drug tomorrow faces an adcom over its own conditional approval.

The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.

Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.

PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.

But today’s deal with Jiangsu Hengrui doesn’t mean that the group is turning away from an earlier tie-up with Nerviano.

After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.

The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.

Momelotinib gains full US approval in a broader setting than expected, validating GSK’s $1.9bn buyout of Sierra Oncology.

Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer. 

Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.

The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.